Abstract | BACKGROUND: METHODS: Japanese White rabbits were randomly fed normal rabbit chow LRC-4 (n=10, control) or a food admixture of LRC-4 and 0.75% JTT-705 (n=10, treated) for 7 months. An in vivo kinetics study of apo A-I was performed by injecting rabbit 125I-apo A-I, and apo A-I mRNA levels were quantified by RT-PCR. RESULTS:
JTT-705 significantly inhibited CETP activities, increased serum levels of HDL-cholesterol (C), HDL2-C, HDL- phospholipid, and apo A-I, and decreased HDL-triglyceride levels. The synthetic rate of apo A-I was higher in the treated rabbits than in control rabbits (13.7 +/- 2.6 versus 9.5 +/- 1.3 mg/kg per day, P < 0.05), while the fractional catabolic rate was similar in the two groups. JTT-705 increased apo A-I mRNA levels in the liver without affecting those in the intestine. CONCLUSION: Inhibition of CETP activity by JTT-705 increases HDL levels by increasing the synthesis of apo A-I, suggesting that it could be a promising therapeutic approach for atherosclerosis.
|
Authors | Eiso Shimoji, Bo Zhang, Ping Fan, Keijiro Saku |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 172
Issue 2
Pg. 247-57
(Feb 2004)
ISSN: 0021-9150 [Print] Ireland |
PMID | 15019534
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amides
- Apolipoprotein A-I
- Carrier Proteins
- Cholesterol Ester Transfer Proteins
- Cholesterol, HDL
- Esters
- Glycoproteins
- HDL-triglyceride
- Lipoproteins, HDL
- Lipoproteins, HDL2
- Sulfhydryl Compounds
- Triglycerides
- dalcetrapib
|
Topics |
- Amides
- Animals
- Apolipoprotein A-I
(biosynthesis, blood, genetics)
- Carrier Proteins
(antagonists & inhibitors)
- Cholesterol Ester Transfer Proteins
- Cholesterol, HDL
(blood)
- Esters
- Gene Expression
- Glycoproteins
- Lipoproteins, HDL
(blood)
- Lipoproteins, HDL2
- Male
- Rabbits
- Sulfhydryl Compounds
(pharmacology)
- Triglycerides
(blood)
|